ACTRN12616001351404已完成1 期
A single centre, double blind, randomised , parallel group, ascending single and multiple dose, safety and tolerability, pharmacokinetic and pharmacodynamic study of oral ketamine in healthy volunteer and patients with a history of depression or anxiety cohorts.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •Subjects will be eligible for enrolment for Cohorts 1, 2, 3 and 5: on the basis of:
- •a)Provide written informed consent
- •b)Male or non-pregnant females
- •c)Aged 18 to 55 years on the day of consent
- •d)Body Mass Index greater than 18 and less than 30kg/m2 on day of consent
- •e)Healthy individuals as determined by medical history, physical examination, ECG, vital signs and laboratory tests
- •f)HIV and Hepatitis B and C negative
- •g)Non-smoker (for at least 6 months prior to the date of consent).
- •h)Drug free as determined by urine drug testing
- •Subjects will be eligible for enrolment for Cohort 4 on the basis of:
- •a)Provide written informed consent
- •b)Male or non-pregnant females
- •c)Aged 18 to 60 years on the day of consent
- •d)Body Mass Index greater than 18 and less than 35 kg/m2 on day of consent
- •e)Healthy individuals as determined by medical history, physical examination, ECG, vital signs and laboratory tests
- •f)HIV and Hepatitis B and C negative
- •g)Previously Diagnosed DSM-5 Major Depressive Disorder (MDD) (n=6) or Generalized Anxiety Disorder (GAD) /Social Anxiety Disorder (SAD) (n=6)
- •h)An inadequate response, ie treatment was not successful, treatment with at least 2 prescribed antidepressants
- •i)MADRS score of at least 20 (MDD) or HAM-A score of 18 (GAD/SAD)
- •j)Psychotropic medication and/or psychotherapy regime is stable i.e no change to drugs or dose or visit schedule within previous four weeks
- •k) Previous positive response to off label SC injection ketamine use as determined by documentation of a 50% change in previous Hamilton Anxiety Scale (HAM-A) for MDD, Spielberger State Anxiety inventory (SSAI) plus Fear Questionnaire (FQ) for SAD
- •l)Drug free as determined by urine drug testing
排除标准
- •Subjects will be excluded for Cohorts 1, 2, 3 and 5: on the basis of:
- •a)Evidence from medical history, physical or laboratory examinations of clinically significant neurologic, psychiatric, cardiac, respiratory, renal, hepatic, endocrine, gastrointestinal, immunological condition or any other diagnosed conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug, interfere with the ability to accurately record study measurements or which may potentiate or predispose to undesired effects.
- •b)Participants receiving treatment with monoamine oxidase inhibitors, vasoconstriction agents, thyroxine or benzodiazepines.
- •c)Any clinically significant history of alcohol or drug abuse or dependency including ketamine or its excipients.
- •d)Any clinically significant illness in the 30 days prior to dosing day 1.
- •e)Any clinically significant infection or febrile illness in the five days prior to dosing day 1.
- •f)Clinically significant Abnormal ECG at the screening visit
- •g)Females who are pregnant or breastfeeding
- •h)Females who are not using effective contraception for the prevention of pregnancy ie prescribed hormonal contraceptives or other reliable methods
- •i)Participation in any drug study in the 60 days preceding dosing day 1
- •j)Participants who do not consent to their GP being contacted prior to the commencement of the study, if necessary, about their medical history or after the study about any adverse results or reactions
- •k)Participants who, in the opinion of the Investigator, do not understand the information and procedures of the study, or would not be compliant with them (in particular the study restrictions and risks involved).
- •l)Any participation for whom the Investigator believes, for any reason, inclusion would not be an acceptable risk
- •m)Subject with any clinically significant abnormality or abnormal laboratory test results found during medical screening
- •n)History of mental illness requiring medication or treatment by a physician
- •Subjects will be excluded for Cohort 4: on the basis of:
- •a)Evidence from medical history, physical or laboratory examinations of clinically significant neurologic, cardiac, respiratory, renal, hepatic, endocrine, gastrointestinal, immunological condition or any other diagnosed conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug, interfere with the ability to accurately record study measurements or which may potentiate or predispose to undesired effects.
- •b)Participants receiving treatment with monoamine oxidase inhibitors, vasoconstriction agents, thyroxine or benzodiazepines.
- •c)Any clinically significant history of alcohol or drug abuse or dependency.
- •d)Any clinically significant illness in the 30 days prior to dosing day 1.
- •e)Any clinically significant infection or febrile illness in the five days prior to dosing day 1.
- •f)Clinically significant Abnormal ECG at the screening visit
- •g)Females who are pregnant or breastfeeding
- •h)Females who are not using effective contraception for the prevention of pregnancy ie prescribed hormonal contraceptives or other reliable methods
- •i)Participation in any drug study in the 60 days preceding dosing day 1
- •j)Participants who do not consent to their GP being contacted prior to the commencement of the study, if necessary, about their medical history or after the study about any adverse results or reactions
- •k)Participants who, in the opini
研究者
相似试验
撤回
1 期
A single centre, double blind, randomised, parallel group, single dose signal study of R-107 in participants with DSM-5 specific phobiaSpecific phobia to spidersMental Health - Other mental health disordersACTRN12618001381279Douglas Pharmaceuticals Ltd12
尚未招募
2 期
A single centre, double blind, randomised, parallel group study to explore the efficacy and tolerability of intranasal fluticasone propionate compared with placebo delivered by the OptiNose device in adult subjects with chronic rhinosinusitis.chronic rhinosinusitis10046304NL-OMON30750OptiNose UK Ltd40
招募中
不适用
Clinical study of efficacy and safety of Chung A Won in Women’s patients with osteoporosisDiseases of the musculo-skeletal system and connective tissueKCT0000594Cheonan Korean Medicine Hospital of Daejeon University106
已完成
3 期
A clinical study to test the effect of 2 product formulations against a control, on gingival conditions and plaque levels, in an experimental gingivitis model after 3 weeks of home use.CTRI/2009/091/000626Smile Care Clinic Pvt Ltd100
已完成
不适用
To evaluate how safe and effective Salacia is in Obese or Overweight subjectsCTRI/2018/03/012414OmniActive Health Technologies Ltd28